Skip to content

Xencor XNCR Unrealized gains (losses) on available-for-sale securities

Unrealized gains (losses) on available-for-sale securities at other companies

AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$122K+15.3%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
-$1.55M-299%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$74K
Arrowhead Research logo
Arrowhead ResearchARWR
-$6.93M-1,162%

Other financials

Income statement

See full
Revenue$4.5M-86.2%
Operating income-$77.9M-80.3%
Net income-$128.9M-166%
EPS (diluted)-$1.71-159%

Balance sheet

See full
Cash & equivalents$14.2M-64.3%
Total debt$175.2M-21.2%
Total equity$515.6M-19.4%
Total assets$736.8M-18.6%

Cash flow

See full
Operating cash flow-$67.6M-317%
CapEx$610.0K-57.8%
Free cash flow-$68.2M-286%

Valuation

See full
Market cap$1.09B+79.8%
Enterprise value$1.25B+58.6%
P/S11.2×+6.4×

Profitability

See full
Operating margin-217.9%+425pp
Net margin-177.1%+16.5pp
FCF margin-194%+166pp

Returns & leverage

See full
Return on equity-29.8%-2.7pp
Debt / equity0.3×0.0×
Current ratio6.6×+0.7×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.

The official record: Xencor’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xencor's unrealized gains (losses) on available-for-sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xencor's unrealized gains (losses) on available-for-sale securities?
Xencor (XNCR) reported unrealized gains (losses) on available-for-sale securities of -$1.55M in Q1 2026.
How has Xencor's unrealized gains (losses) on available-for-sale securities changed year-over-year?
Xencor's unrealized gains (losses) on available-for-sale securities decreased by 252.2% year-over-year, from $1.02M to -$1.55M.
What is the long-term trend for Xencor's unrealized gains (losses) on available-for-sale securities?
Over 4 years (2021 to 2025), Xencor's unrealized gains (losses) on available-for-sale securities has grown at a 9.0% compound annual growth rate (CAGR), from -$1.58M to $2.24M.
What does unrealized gains (losses) on available-for-sale securities mean?
This metric represents the change in the fair value of available-for-sale debt securities that has not yet been realized through a sale. It captures unrealized gains or losses resulting from fluctuations in market interest rates and credit conditions for the company's investment portfolio. Monitoring this figure helps investors understand the volatility and potential liquidity impact of the company's treasury management strategy.